Amarin appoints Murray Stewart to Board; 75% of directors new in last 12 months

AMARIN CORP PLCUK

Murray Stewart, DM FRCP, appointed to Amarin Board effective January 9, 2023.
Stewart brings 30+ years cardiometabolic experience; formerly CMO at GSK and Rhythm Pharmaceuticals.
Approximately 75% of independent directors are new, with six appointments over the past 12 months.
Stewart will serve until 2023 AGM and then stand for election by shareholders.
He will receive standard non-employee director equity awards and annual fees.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Murray Stewart

Director

AMRN · AMARIN CORP PLCUK

Effective: 2023-01-09
Filed: January 10, 2023, 6:59 PM ET

On January 9, 2023, the Board of Directors (the “Board”) of Amarin Corporation plc (the “Company”), as part of the ongoing Board refreshment process, appointed Murray Stewart, DM, FRCP, to the Board to a term commencing immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Murray Stewart was appointed as Director at AMARIN CORP PLCUK.

Action: appointed
Role: Director

Exact text from the filing

On January 9, 2023, the Board of Directors (the “Board”) of Amarin Corporation plc (the “Company”), as part of the ongoing Board refreshment process, appointed Murray Stewart, DM, FRCP, to the Board to a term commencing immediately.

View on SEC.gov

AMARIN CORP PLCUK filing history →

Source: SEC EDGAR

accession 0001193125-23-005176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.